Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Azelastine/Fluticasone Nasal Spray vs Dymista
NCT06180083Phase 1Completed
- Sponsor
- Humanis
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of azelastine + fluticasone in allergic rhinitis (AR) (2 arms), sponsored by Humanis. Primary endpoints: Maximum measured plasma concentration at 120 hours and Area under the plasma concentration versus time curve from zero to last quantifiable concentration at 120 hours. Started Mar 2023; status: completed.
02
Drugs
azelastine + fluticasone
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06180083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180083.